SAN DIEGO, June 4, 2011 /PRNewswire/ — Amylin Pharmaceuticals,
Inc. (Nasdaq:
AMLN) today announced results from a study that showed
treatment with metreleptin, an investigational treatment that is an
analog of the human hormone leptin, improved diabetes and lipid
control in patients with partial lipodystrophy. Data from this
study, the first findings from patients receiving metreleptin
through Amylin’s lipodystrophy expanded access program, were
presented at the 93rd Annual Meeting and Expo of The Endocrine
Society (ENDO) in Boston.

In this study, being conducted under a treatment IND authorized
by the U.S. Food and Drug Administration (FDA), metreleptin is made
available to patients with rare forms of lipodystrophy who have one
or more metabolic abnormalities, including diabetes and
hypertriglyceridemia (high levels of triglycerides in the
bloodstream). This analysis focused on patients with partial
lipodystrophy who had received treatment for at least six months.
Treatment with metreleptin resulted in improvements from baseline
in A1C (a measure of average blood sugar over three months) and
triglycerides. Further, the majority of patients receiving
metreleptin were able to reduce or discontinue treatment with
pre-existing diabetes medications, including insulin.  

“We are committed to assisting patients who are living with
lipodystrophy, a chronic and often debilitating disease that is not
adequately managed by existing therapies,” said Christian Weyer,
M.D., senior vice president, research and development, Amylin
Pharmaceuticals. “Our expanded access program enables us to provide
patients with metreleptin while we continue working with the FDA to
make the medicine more broadly available to patients with this rare
disorder.”

Results of this analysis were presented by Suma Amarnath, M.D.,
a member of the research team led by Elif Oral, M.D. during an
or

‘/>”/>

SOURCE